On March 24, 2026, Harrow, Inc. (NASDAQ: HROW), a prominent provider of ophthalmic disease management solutions in North America, announced its intention to offer an additional $50 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030. This offering is aimed at qualified institutional buyers in the United States and certain non-U.S. persons outside the United States, in accordance with Rule 144A and Regulation S under the Securities Act of 1933. The new notes will be issued as additional notes under the same indenture governing the existing $250 million aggregate principal amount of 8.625% senior notes due 2030, which were previously issued on September 12, 2025. The new notes will be treated as a single series with the existing notes and will share the same terms, except for the date of issuance and the issue price. Harrow intends to utilize the net proceeds from this offering for general corporate purposes, which may include funding new product launches, product development activities, and strategic business development opportunities. However, the company cautioned that there is no assurance it will complete the offering on favorable terms or at all, and it may decide to withdraw from the offering before completion. This announcement reflects Harrow's ongoing commitment to enhancing its growth and operational capabilities in the ophthalmic sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.